xenoport inc (XNPT) Key Developments
XenoPort, Inc. Proposes Amendments to Amended and Restated Certificate of Incorporation
Apr 10 15
The 2015 annual meeting of stockholders of XenoPort, Inc. will be held on May 19, 2015. At the meeting the shareholders will approve an amendment to the company's amended and restated certificate of incorporation to eliminate the supermajority voting requirement for amendments to the company's amended and restated bylaws and the shareholders will approve an amendment to the company's amended and restated certificate of incorporation to increase the total number of shares of common stock authorized for issuance from 100 million shares to 200 million shares.
Xenoport, Inc. Announces Resignation of Gianna M. Bosko as Senior Vice President, Chief Legal Officer and Secretary, Effective as of February 28, 2015
Feb 19 15
On February 13, 2015, Xenoport, Inc. announced Gianna M. Bosko notified the Company of her decision to resign from her position as senior vice president, chief legal officer and secretary of the Company, effective as of February 28, 2015. Pursuant to a consulting agreement, made effective March 1, 2015, Ms. Bosko will be available through March 1, 2016 to provide additional consulting services to the Company in the field of general legal, corporate governance and business matters, at a rate of $500.00 per hour.
Xenoport, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Sales Guidance for the Year 2015
Feb 19 15
Xenoport, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, total revenues were $7,091,000 against $2,879,000 a year ago. The increase in revenues in the fourth quarter ended December 31, 2014 was principally due to HORIZANT net product sales. Loss from operation was $17,595,000 against $19,059,000 a year ago. Net loss was $17,657,000 or $0.28 per basic and diluted share against $19,138,000 or $0.40 per basic and diluted share a year ago.
For the year, total revenues were $46,868,000 against $7,951,000 a year ago. Loss from operation was $49,099,000 against $85,628,000 a year ago. The increase in revenues for the year ended December 31, 2014 was principally due both to the recognition of $25.0 million in collaboration revenue related to an arbaclofen placarbil (AP) licensing agreement with Indivior, as well as to increased HORIZANT net product sales. Net loss was $49,333,000 or $0.81 per basic and diluted share against $85,883,000 or $1.81 per basic and diluted share a year ago.
The company announced that it expects HORIZANT net product sales for 2015 to be in the range of $39.0 million to $43.0 million and the net use of cash for 2015 to be in the range of $75.0 million to $85.0 million (net use of cash is the difference between the anticipated balances of cash and cash equivalents plus short-term investments at December 31, 2015, excluding the net proceeds from the sale of the convertible notes completed in February 2015, and the actual balances at December 31, 2014).
Xenoport, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:30 AM
Feb 18 15
Xenoport, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Ronald W. Barrett, Co-Founder, Chief Executive Officer and Director.
Xenoport, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM
Feb 18 15
Xenoport, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.